JP2022533939A - 線維芽細胞増殖因子受容体キナーゼの阻害剤 - Google Patents

線維芽細胞増殖因子受容体キナーゼの阻害剤 Download PDF

Info

Publication number
JP2022533939A
JP2022533939A JP2021567059A JP2021567059A JP2022533939A JP 2022533939 A JP2022533939 A JP 2022533939A JP 2021567059 A JP2021567059 A JP 2021567059A JP 2021567059 A JP2021567059 A JP 2021567059A JP 2022533939 A JP2022533939 A JP 2022533939A
Authority
JP
Japan
Prior art keywords
optionally substituted
pharmaceutically acceptable
solvate
acceptable salt
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021567059A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020236524A5 (https=
JP2022533939A5 (https=
Inventor
カルドー，ステファン，ダブリュー．
ティホナス，ジョン
Original Assignee
キネート バイオファーマ インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キネート バイオファーマ インク． filed Critical キネート バイオファーマ インク．
Publication of JP2022533939A publication Critical patent/JP2022533939A/ja
Publication of JPWO2020236524A5 publication Critical patent/JPWO2020236524A5/ja
Publication of JP2022533939A5 publication Critical patent/JP2022533939A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2021567059A 2019-05-17 2020-05-14 線維芽細胞増殖因子受容体キナーゼの阻害剤 Pending JP2022533939A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962849534P 2019-05-17 2019-05-17
US62/849,534 2019-05-17
US201962907491P 2019-09-27 2019-09-27
US62/907,491 2019-09-27
PCT/US2020/032939 WO2020236524A1 (en) 2019-05-17 2020-05-14 Inhibitors of fibroblast growth factor receptor kinases

Publications (3)

Publication Number Publication Date
JP2022533939A true JP2022533939A (ja) 2022-07-27
JPWO2020236524A5 JPWO2020236524A5 (https=) 2023-05-08
JP2022533939A5 JP2022533939A5 (https=) 2023-05-08

Family

ID=73458745

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021567059A Pending JP2022533939A (ja) 2019-05-17 2020-05-14 線維芽細胞増殖因子受容体キナーゼの阻害剤

Country Status (7)

Country Link
US (1) US20230174535A1 (https=)
EP (1) EP3969442A4 (https=)
JP (1) JP2022533939A (https=)
CN (1) CN114127051A (https=)
AU (1) AU2020278566A1 (https=)
CA (1) CA3139161A1 (https=)
WO (1) WO2020236524A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
EP4161657A1 (en) * 2020-06-05 2023-04-12 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases
IL298760A (en) 2020-06-05 2023-02-01 Kinnate Biopharma Inc Fibroblast growth factor receptor kinase inhibitors
WO2023107870A1 (en) * 2021-12-08 2023-06-15 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases
AU2022407440A1 (en) * 2021-12-08 2024-06-20 Kinnate Biopharma Inc. Solid state forms of an fgfr inhibitor
WO2024109799A1 (zh) * 2022-11-22 2024-05-30 西藏海思科制药有限公司 一种嘧啶衍生物及其在医药上的应用
WO2025024665A1 (en) * 2023-07-26 2025-01-30 Kinnate Biopharma Inc. Treatment of cancer with a cdk inhibitor

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007531754A (ja) * 2004-04-02 2007-11-08 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド ６，６−二環置換されたヘテロ二環式タンパク質キナーゼ阻害剤
JP2009509961A (ja) * 2005-09-22 2009-03-12 ブリストル−マイヤーズ スクイブ カンパニー キナーゼモジュレーターとして有用な縮合へテロ環化合物
JP2009518303A (ja) * 2005-12-02 2009-05-07 バイエル・ヘルスケア・エルエルシー 過剰増殖性疾患および血管新生と関連する疾患を処置するために有用な置換された４−アミノ−ピロロトリアジン誘導体
WO2013108809A1 (ja) * 2012-01-19 2013-07-25 大鵬薬品工業株式会社 ３，５－二置換ベンゼンアルキニル化合物及びその塩
WO2016159327A1 (ja) * 2015-03-31 2016-10-06 大鵬薬品工業株式会社 ３，５－二置換ベンゼンアルキニル化合物の結晶
WO2018028438A1 (zh) * 2016-08-09 2018-02-15 南京天印健华医药科技有限公司 作为fgfr抑制剂的杂环化合物
WO2018121650A1 (zh) * 2016-12-29 2018-07-05 南京明德新药研发股份有限公司 Fgfr抑制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0428082D0 (en) * 2004-12-22 2005-01-26 Welcome Trust The Ltd Therapeutic compounds
US7723336B2 (en) * 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
GB201503590D0 (en) * 2015-03-03 2015-04-15 Davis Adrian Topical formulation
WO2017139509A1 (en) * 2016-02-12 2017-08-17 Purdue Research Foundation Manipulating 3d virtual objects using hand-held controllers
US10685111B2 (en) * 2016-10-31 2020-06-16 Crowdstrike, Inc. File-modifying malware detection

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007531754A (ja) * 2004-04-02 2007-11-08 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド ６，６−二環置換されたヘテロ二環式タンパク質キナーゼ阻害剤
JP2009509961A (ja) * 2005-09-22 2009-03-12 ブリストル−マイヤーズ スクイブ カンパニー キナーゼモジュレーターとして有用な縮合へテロ環化合物
JP2009518303A (ja) * 2005-12-02 2009-05-07 バイエル・ヘルスケア・エルエルシー 過剰増殖性疾患および血管新生と関連する疾患を処置するために有用な置換された４−アミノ−ピロロトリアジン誘導体
WO2013108809A1 (ja) * 2012-01-19 2013-07-25 大鵬薬品工業株式会社 ３，５－二置換ベンゼンアルキニル化合物及びその塩
WO2016159327A1 (ja) * 2015-03-31 2016-10-06 大鵬薬品工業株式会社 ３，５－二置換ベンゼンアルキニル化合物の結晶
WO2018028438A1 (zh) * 2016-08-09 2018-02-15 南京天印健华医药科技有限公司 作为fgfr抑制剂的杂环化合物
WO2018121650A1 (zh) * 2016-12-29 2018-07-05 南京明德新药研发股份有限公司 Fgfr抑制剂

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
C.G.WERMUTH編, 『最新 創薬化学 上巻』, JPN6014041942, 15 August 1998 (1998-08-15), pages 235 - 271, ISSN: 0005440429 *
野崎正勝 等, 創薬化学, vol. 第１版, JPN6012059719, 1995, pages 98 - 99, ISSN: 0005440430 *

Also Published As

Publication number Publication date
WO2020236524A1 (en) 2020-11-26
CA3139161A1 (en) 2020-11-26
AU2020278566A1 (en) 2021-12-23
EP3969442A1 (en) 2022-03-23
CN114127051A (zh) 2022-03-01
EP3969442A4 (en) 2023-08-02
US20230174535A1 (en) 2023-06-08

Similar Documents

Publication Publication Date Title
JP2022533939A (ja) 線維芽細胞増殖因子受容体キナーゼの阻害剤
JP2022532034A (ja) Ｒａｆキナーゼの阻害剤
CN113874381A (zh) Raf激酶的抑制剂
US11008323B2 (en) Substituted tricyclic 1,4-benzodiazepinone derivatives as allosteric modulators of group II metabotropic glutamate receptors
JP6967302B2 (ja) アザアリール誘導体、その製造方法および薬学上の応用
US11814384B2 (en) Inhibtors of Raf kinases
JP2023529867A (ja) 線維芽細胞増殖因子受容体キナーゼの阻害剤
EP4161657A1 (en) Inhibitors of fibroblast growth factor receptor kinases
WO2021067696A1 (en) Antagonists of the muscarinic acetylcholine receptor m4
CN119403803A (zh) Parg抑制剂
US20260092061A1 (en) Compounds for targeted protein degradation
JP6329961B2 (ja) 置換ピラゾロ［３，４−ｄ］ピリミジン化合物、その製造及びシグマ受容体リガンドとしての使用
TW202502751A (zh) Cbl-b抑制劑
CN121358733A (zh) Fgfr2/3选择性抑制剂、药物组合物及其应用
JP2021527678A (ja) Ｆｇｆｒ阻害剤、その製造方法および応用
JP2023515729A (ja) Ｃｄｋ９阻害剤としての多環式アミド系誘導体、その調製方法及び用途
WO2023107870A1 (en) Inhibitors of fibroblast growth factor receptor kinases
US20060264431A1 (en) P38 inhibitors and methods of use thereof
CN116438179B (zh) 作为ret激酶抑制剂的吡唑衍生物
HK40064672A (en) Inhibitors of fibroblast growth factor receptor kinases
JP6337092B2 (ja) 三環式トリアゾール系化合物
CN118439991B (zh) 一类rbj小分子抑制剂
HK40114068A (zh) Raf激酶的抑制剂
TW202529762A (zh) 作為ｐｄｅ４ｂ抑制劑的氘代雜環化合物及其應用
HK40063842A (en) Inhibitors of raf kinases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211110

RD12 Notification of acceptance of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7432

Effective date: 20221208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230425

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230425

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240313

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240327

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241017